Navigation Links
NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/10/2008

SAN MATEO, Calif., Nov. 10 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York City on Tuesday, November 11, 2008. Mr. DiTonno and Stephen Ghiglieri, Chief Financial Officer, will also be available to respond to questions during the breakout session immediately following the presentation.

Event: Rodman & Renshaw 10th Annual Healthcare Conference

Date: Tuesday, November 11, 2008

Time: 2:25 p.m. ET

Place: New York Palace Hotel, Holmes II (4th Floor)

The presentation will be webcast live and can be accessed by visiting the investor relations section of NeurogesX' website at http://www.neurogesx.com. The webcast will be archived for 15 days.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain condi
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NeurogesX Reports Third Quarter 2008 Results
2. NeurogesX to Report Third Quarter 2008 Financial Results
3. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
4. NeurogesX Responds to EMEAs Day 120 Questions
5. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
6. NeurogesX Reports Second Quarter 2008 Results
7. NeurogesX to Report Second Quarter 2008 Financial Results
8. NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998
9. NeurogesX to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
10. NeurogesX Reports First Quarter 2008 Results
11. NeurogesX to Report First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Ireland , September 18, 2014 ... and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has ... "Biocompatible Materials - Global Strategic Business ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes ... in US$ Million by the following ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... the "Global N-acetylcysteine Industry Report 2014" ... Global N-acetylcysteine Industry Report 2014 is a professional ... the global N-acetylcysteine industry. The report ... definitions, classifications, applications and industry chain structure. The ...
(Date:9/18/2014)... LOUIS , Sept. 18, 2014  U.S. biotech ... by signing an exclusive license for technology developed by ... control gene expression in plants, including for applications in ... The technology was developed under the ... officer at Kultevat and former president of the Danforth ...
(Date:9/18/2014)... septembre 2014 Mapi, société créée à ... a été depuis 40 ans l,un des ... traditionnelles par des évaluations recentrées sur le ... impacts économiques des traitements. Logo ... A cours d,une récente conférence téléphonique avec ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2Kultevat obtains license of gene switch technology 21974 - 2014 - Mapi fĂȘte ses 40 ans 2
... August 24 Health Robotics today reported,that on ... McKesson, it,has received categorical support from virtually all ... few days since the partnership was publicly announced.,While ... on industry events, a few reactions to the ...
... , , , NEW YORK, Aug. ... the pre-disease collection, processing and long-term storage of adult stem cells for ... Technology Company with the New York Department of Taxation and Finance, for ... The Company has notified certain shareholders that, as a result of this ...
... OSLO, August 24 PCI Biotech Holding ... delivery of cancer therapeutics,today announced that the first ... with the lead candidate Amphinex(R), which uses a ... at the,University College Hospital (UCH) in London. PCI,s ...
Cached Biology Technology:Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership 2Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership 3Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership 4NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20% 2NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20% 3PCI Biotech Commences Phase I/II Trials of Amphinex(R) 2
(Date:9/18/2014)... 2014Many Americans across racial and ethnic groups describe ... on their day-to-day life, more so than other ... speech (57% of African-Americans, 49% of non-Hispanic whites, ... asked which disease or ailment is the worst ... among African-Americans followed by AIDS/HIV. Hispanics and ...
(Date:9/18/2014)... carbon and nitrogen comprise all spheres of our ... have caused imbalances and perturbations that resulted in ... GHGs result in climate changes which influence the ... the atmosphere. Understanding these feedback mechanisms has become ... science during the past three decades. , In ...
(Date:9/18/2014)... is probably the ultimate form of camouflage: you don,t ... this strategy is not as uncommon as you might ... County, USA, explains that the larval life stages of ... part of the anatomy that most creatures cannot make ... have to shield each individual eye unit with an ...
Breaking Biology News(10 mins):Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Greenhouse gas research enters a new era 2Transparent larvae hide opaque eyes behind reflections 2
... ROCKVILLE, MD, USA/BEIJING, CHINA -- The global fight against ... and the China National Biotec Group (CNBG) announce that ... tuberculosis (TB) vaccines. The agreement between the leading non-profit ... corporation in China signals a commitment by both to ...
... Barbara, Calif.) When UC Santa Barbara geochemist David Valentine ... bacteria blooms had consumed almost all of the deepwater methane ... people were skeptical. How, they asked, could almost all of ... disappear? In a new study published in the ...
... location and the political instability in the region have kept ... , But Hyongki Lee, a University of Houston civil engineering ... this mysterious region _ studying it from space. , Lee ... He plans to use unanalyzed satellite images to survey the ...
Cached Biology News:Aeras and CNBG sign agreement on tuberculosis vaccine R&D 2UCSB scientists say topography played key role in Deepwater Horizon disaster 2UCSB scientists say topography played key role in Deepwater Horizon disaster 3UCSB scientists say topography played key role in Deepwater Horizon disaster 4University of Houston wins NASA grant to study Congo River Basin 2
Mouse anti-hepatitis delta virus Class: Antibody Product Group: Bacterial and Viral Antigen...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
Biology Products: